Literature DB >> 26013028

Treating Burkitt Lymphoma in Adults.

Carla Casulo1, Jonathan Friedberg.   

Abstract

Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.

Entities:  

Mesh:

Year:  2015        PMID: 26013028     DOI: 10.1007/s11899-015-0263-4

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  37 in total

1.  Malignant tumors in African children. With special reference to malignant lymphoma.

Authors:  G T O'CONOR; J N DAVIES
Journal:  J Pediatr       Date:  1960-04       Impact factor: 4.406

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.

Authors:  Yinfei Tan; Eleonora Sementino; Jianming Pei; Yuwaraj Kadariya; Timothy K Ito; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2015-03-20       Impact factor: 4.742

5.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

6.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors:  Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

7.  Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.

Authors:  C Soussain; C Patte; M Ostronoff; A Delmer; F Rigal-Huguet; N Cambier; P Y Leprisé; S François; P Cony-Makhoul; J L Harousseau
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

8.  An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

Authors:  G M Mead; M R Sydes; J Walewski; A Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; J McKendrick; S P Stenning; D Wright; P Norbert
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

Review 9.  Burkitt's lymphoma in Africa, a review of the epidemiology and etiology.

Authors:  Jackson Orem; Edward Katongole Mbidde; Bo Lambert; Silvia de Sanjose; Elisabete Weiderpass
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

10.  Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.

Authors:  B Tolani; R Gopalakrishnan; V Punj; H Matta; P M Chaudhary
Journal:  Oncogene       Date:  2013-06-24       Impact factor: 9.867

View more
  12 in total

1.  Burkitt and Burkitt-Like Lymphomas: a Systematic Review.

Authors:  Khalil Saleh; Jean-Marie Michot; Valérie Camara-Clayette; Yegor Vassetsky; Vincent Ribrag
Journal:  Curr Oncol Rep       Date:  2020-03-06       Impact factor: 5.075

2.  Mandibular sporadic Burkitt lymphoma in an adult patient: A case report and review of the literature.

Authors:  Nahal Azimi; Farnoosh Razmara; Samira Derakhshan; Neda Kardouni Khoozestani
Journal:  Clin Case Rep       Date:  2021-07-21

3.  Intraoral EBV-positive sporadic Burkitt lymphoma in an elderly patient with bilateral presentation.

Authors:  Ricardo Martínez Pedraza; Lady Paola Aristizabal Arboleda; Celeste Sánchez-Romero; Jesús Alfonso Aguirre Quiñones; Carlos de Jesús Mata Tovar; Javier Rendón Henao; Oslei Paes de Almeida
Journal:  Autops Case Rep       Date:  2019-09-18

4.  Inhibition of HIF-1α by Atorvastatin During 131I-RTX Therapy in Burkitt's Lymphoma Model.

Authors:  Eun-Ho Kim; Hae Young Ko; A Ram Yu; Hyeongi Kim; Javeria Zaheer; Hyun Ji Kang; Young-Cheol Lim; Kyung Deuk Cho; Hyun-Yoo Joo; Min Kyoung Kang; Jae Jun Lee; Seung-Sook Lee; Hye Jin Kang; Sang Moo Lim; Jin Su Kim
Journal:  Cancers (Basel)       Date:  2020-05-11       Impact factor: 6.639

5.  Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma.

Authors:  Yi Xie; Mengyu Jia; Jumei Shi; Yi Tao
Journal:  Cancer Med       Date:  2020-03-11       Impact factor: 4.452

6.  Nicotinamide adenine dinucleotide phosphate oxidase inhibitor induces apoptosis on Epstein-Barr virus positive B lymphoma cells.

Authors:  Choong Heon Ryu; Sung Hyun Kim; Dae Young Hur
Journal:  Anat Cell Biol       Date:  2020-12-31

7.  A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study.

Authors:  Mei-Ting Chen; Fei Pan; Yung-Chang Chen; Wei Zhang; Hui-Juan Lv; Zhao Wang; Huang-Ming Hong; Xiao-Jie Fang; Ya-Wen Wang; Tao Pan; Li-Qun Zou; Hong-Qiang Guo; Ke Xie; Li-Min Chen; Xiao-Qian Li; Yu-Yi Yao; Ze-Geng Chen; Hua-Wei Weng; Xu-Dong Li; Yuan-Yuan Shen; Hui Zhou; Hong-Wei Xue; Hui-Lai Zhang; He Huang; Tong-Yu Lin
Journal:  BMC Cancer       Date:  2022-01-07       Impact factor: 4.430

8.  Triclosan induces apoptosis in Burkitt lymphoma-derived BJAB cells through caspase and JNK/MAPK pathways.

Authors:  Mohammad A Alfhili; Hosni A M Hussein; Youngyong Park; Myon Hee Lee; Shaw M Akula
Journal:  Apoptosis       Date:  2021-01-02       Impact factor: 4.677

9.  Intestinal atresia following chemotherapy, presenting as superior mesenteric artery syndrome: A case report.

Authors:  Xing Wang; Jian-Zhong Li; Ying-Hui Yang; Xiao-Li Huang; Yu Wang; Bin Wu
Journal:  Mol Clin Oncol       Date:  2017-07-28

10.  [Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].

Authors:  D Y Tu; M Zhang; W J Yin; L Y Xu; W Sang; Z Y Li; K L Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.